多病症指南的建议和质量：系统综述。

IF 12.5 1区医学 Q1 CELL BIOLOGY

Ageing Research Reviews Pub Date : 2024-11-10 DOI:10.1016/j.arr.2024.102559

Zijun Wang , Di Zhu , Huayu Zhang , Ling Wang , Hongfeng He , Zhewei Li , Bingyi Wang , Jie Zhang , Xiaoqing Li , Hanna Tuinhof , Barbara C. van Munster , Yaolong Chen , Janne Estill

{"title":"多病症指南的建议和质量：系统综述。","authors":"Zijun Wang , Di Zhu , Huayu Zhang , Ling Wang , Hongfeng He , Zhewei Li , Bingyi Wang , Jie Zhang , Xiaoqing Li , Hanna Tuinhof , Barbara C. van Munster , Yaolong Chen , Janne Estill","doi":"10.1016/j.arr.2024.102559","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>As the population is aging, multimorbidity has become an increasingly important global health challenge. Clinical practice guidelines are essential references to guide daily practice for health care providers. This systematic review aims to assess whether existing multimorbidity guidelines adhered to the principles outlined in a previously developed framework for multimorbidity management recommendations, Ariadne, and evaluate their methodological and reporting quality.</div></div><div><h3>Methods</h3><div>We systematically searched six literature databases and nine guideline platforms from their inception until September 30, 2024. We included guidelines and guideline-like documents on multimorbidity and polypharmacy. Language was limited to English and Chinese. We extracted data related to basic information and guideline development methodology, and categorized guideline recommendations based on the Ariadne framework. We used the Appraisal of Guidelines, Research and Evaluation II (AGREE II) instrument and Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist to evaluate the methodological and reporting quality of the guidelines, respectively.</div></div><div><h3>Result</h3><div>Our systematic review identified 20 eligible guidelines, of which 10 focused on multimorbidity, eight on polypharmacy, and two covered both topics. The mean overall AGREE II score was 27.9 % and the mean compliance rate to the RIGHT reporting checklist 35.1 %. Individualized management was the most frequently addressed of the five steps of the Ariadne framework (n=18 guidelines, 90.0 %), followed by interaction assessment (n=17, 85.0 %).</div></div><div><h3>Conclusion</h3><div>The methodological and reporting quality of multimorbidity guidelines were suboptimal. The recommendations of these guidelines covered primarily the management process of multimorbid patients. Future guidelines should pay more attention to the scientific quality of the development methodology and the feasibility of implementing the guidelines in practice.</div></div><div><h3>Funding</h3><div>Research Unit of Evidence-Based Evaluation and Guidelines (2021RU017), Chinese Academy of Medical Sciences, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"102 ","pages":"Article 102559"},"PeriodicalIF":12.5000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recommendations and quality of multimorbidity guidelines: A systematic review\",\"authors\":\"Zijun Wang , Di Zhu , Huayu Zhang , Ling Wang , Hongfeng He , Zhewei Li , Bingyi Wang , Jie Zhang , Xiaoqing Li , Hanna Tuinhof , Barbara C. van Munster , Yaolong Chen , Janne Estill\",\"doi\":\"10.1016/j.arr.2024.102559\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>As the population is aging, multimorbidity has become an increasingly important global health challenge. Clinical practice guidelines are essential references to guide daily practice for health care providers. This systematic review aims to assess whether existing multimorbidity guidelines adhered to the principles outlined in a previously developed framework for multimorbidity management recommendations, Ariadne, and evaluate their methodological and reporting quality.</div></div><div><h3>Methods</h3><div>We systematically searched six literature databases and nine guideline platforms from their inception until September 30, 2024. We included guidelines and guideline-like documents on multimorbidity and polypharmacy. Language was limited to English and Chinese. We extracted data related to basic information and guideline development methodology, and categorized guideline recommendations based on the Ariadne framework. We used the Appraisal of Guidelines, Research and Evaluation II (AGREE II) instrument and Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist to evaluate the methodological and reporting quality of the guidelines, respectively.</div></div><div><h3>Result</h3><div>Our systematic review identified 20 eligible guidelines, of which 10 focused on multimorbidity, eight on polypharmacy, and two covered both topics. The mean overall AGREE II score was 27.9 % and the mean compliance rate to the RIGHT reporting checklist 35.1 %. Individualized management was the most frequently addressed of the five steps of the Ariadne framework (n=18 guidelines, 90.0 %), followed by interaction assessment (n=17, 85.0 %).</div></div><div><h3>Conclusion</h3><div>The methodological and reporting quality of multimorbidity guidelines were suboptimal. The recommendations of these guidelines covered primarily the management process of multimorbid patients. Future guidelines should pay more attention to the scientific quality of the development methodology and the feasibility of implementing the guidelines in practice.</div></div><div><h3>Funding</h3><div>Research Unit of Evidence-Based Evaluation and Guidelines (2021RU017), Chinese Academy of Medical Sciences, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China</div></div>\",\"PeriodicalId\":55545,\"journal\":{\"name\":\"Ageing Research Reviews\",\"volume\":\"102 \",\"pages\":\"Article 102559\"},\"PeriodicalIF\":12.5000,\"publicationDate\":\"2024-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ageing Research Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1568163724003775\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1568163724003775","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：随着人口老龄化的加剧，多病共存已成为日益重要的全球健康挑战。临床实践指南是指导医疗服务提供者日常实践的重要参考。本系统性综述旨在评估现有的多病症指南是否遵循了之前开发的多病症管理建议框架 Ariadne 中概述的原则，并评估其方法和报告质量：我们系统地检索了六个文献数据库和九个指南平台，检索时间从开始到 2024 年 9 月 30 日。我们纳入了有关多病和多重用药的指南和类似指南的文件。语言仅限于英文和中文。我们提取了与基本信息和指南制定方法相关的数据，并根据阿里阿德涅框架对指南建议进行了分类。我们使用指南、研究和评价评估II（AGREE II）工具和医疗实践指南报告项目（RIGHT）检查表分别评估指南的方法和报告质量：我们的系统综述确定了 20 份符合条件的指南，其中 10 份侧重于多病症，8 份侧重于多重用药，2 份涵盖了这两个主题。AGREE II 的平均总得分为 27.9%，RIGHT 报告清单的平均符合率为 35.1%。在阿里阿德涅框架的五个步骤中，最常涉及的是个体化管理（18 份指南，90.0%），其次是相互作用评估（17 份指南，85.0%）：结论：多病症指南的方法和报告质量均不理想。这些指南的建议主要涉及多病患者的管理过程。未来的指南应更加关注制定方法的科学性和在实践中实施指南的可行性：中国医学科学院循证医学评价与指南研究组（2021RU017），兰州大学基础医学院，甘肃兰州。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Recommendations and quality of multimorbidity guidelines: A systematic review

Background

As the population is aging, multimorbidity has become an increasingly important global health challenge. Clinical practice guidelines are essential references to guide daily practice for health care providers. This systematic review aims to assess whether existing multimorbidity guidelines adhered to the principles outlined in a previously developed framework for multimorbidity management recommendations, Ariadne, and evaluate their methodological and reporting quality.

Methods

We systematically searched six literature databases and nine guideline platforms from their inception until September 30, 2024. We included guidelines and guideline-like documents on multimorbidity and polypharmacy. Language was limited to English and Chinese. We extracted data related to basic information and guideline development methodology, and categorized guideline recommendations based on the Ariadne framework. We used the Appraisal of Guidelines, Research and Evaluation II (AGREE II) instrument and Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist to evaluate the methodological and reporting quality of the guidelines, respectively.

Result

Our systematic review identified 20 eligible guidelines, of which 10 focused on multimorbidity, eight on polypharmacy, and two covered both topics. The mean overall AGREE II score was 27.9 % and the mean compliance rate to the RIGHT reporting checklist 35.1 %. Individualized management was the most frequently addressed of the five steps of the Ariadne framework (n=18 guidelines, 90.0 %), followed by interaction assessment (n=17, 85.0 %).

Conclusion

The methodological and reporting quality of multimorbidity guidelines were suboptimal. The recommendations of these guidelines covered primarily the management process of multimorbid patients. Future guidelines should pay more attention to the scientific quality of the development methodology and the feasibility of implementing the guidelines in practice.

Funding

Research Unit of Evidence-Based Evaluation and Guidelines (2021RU017), Chinese Academy of Medical Sciences, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ageing Research Reviews 医学-老年医学

CiteScore

19.80

自引率

2.30%

发文量

216

审稿时长

55 days

期刊介绍： With the rise in average human life expectancy, the impact of ageing and age-related diseases on our society has become increasingly significant. Ageing research is now a focal point for numerous laboratories, encompassing leaders in genetics, molecular and cellular biology, biochemistry, and behavior. Ageing Research Reviews (ARR) serves as a cornerstone in this field, addressing emerging trends. ARR aims to fill a substantial gap by providing critical reviews and viewpoints on evolving discoveries concerning the mechanisms of ageing and age-related diseases. The rapid progress in understanding the mechanisms controlling cellular proliferation, differentiation, and survival is unveiling new insights into the regulation of ageing. From telomerase to stem cells, and from energy to oxyradical metabolism, we are witnessing an exciting era in the multidisciplinary field of ageing research. The journal explores the cellular and molecular foundations of interventions that extend lifespan, such as caloric restriction. It identifies the underpinnings of manipulations that extend lifespan, shedding light on novel approaches for preventing age-related diseases. ARR publishes articles on focused topics selected from the expansive field of ageing research, with a particular emphasis on the cellular and molecular mechanisms of the aging process. This includes age-related diseases like cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. The journal also covers applications of basic ageing research to lifespan extension and disease prevention, offering a comprehensive platform for advancing our understanding of this critical field.